|
|
| Working
Group 1: Building the Sharing
Framework of Open-ILD |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Nadia Nathan (FR) Killian Hurley
(IE) Name (Country) |
|
| |
| WG1 Leader WG1 Co-Leader WG1 Member |
|
|
|
| Working
with MC members, participants and stakeholders this working group will build
the legal and ethical framework to share cells acrsoss the European Research
Area. It will specifically adress the challenges in obtaining consent from
patients and their families to obtain samples, generate iPSC and share these
with researchers in the field. It will also address challenges in sharing
patient data accross multiple juristictions. |
|
| Working
Group 2: Training in New Technologies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Killian Hurley (IE) Name (Country) Name (Country) |
|
| |
| WG2 Leader WG2
Member WG2 Member |
|
|
|
| This
working group will focus on generating protocols and standard operating
procedures for reprogramming patient blood samples (PBMC) to iPSC, working
with iPSC-derived lung organoids and macrophage. Expert members will also
train researchers in the skills required to work with these cells to generate
a robust preclinical model of ILD. |
|
|
|
| Working
Group 3: Business plan, exploitation and dissemination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Daniel O'Toole (IE) Name (Country) Name (Country) |
|
| |
| WG3 Leader WG3
Member WG3 Member |
|
|
|
This
working group will develop a robust business plan to identify a strategy to
maximise the utilisation of this resource in a financially viable and
operationally sustainable way. It will also develop a dissemination strategy
for the CIG.
|
|
|
|
